Stem Cell-based Therapy for Prevention of Delayed Fracture Union: A Randomized and Prospective Preliminary Study

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

24 patients with distal tibia fractures who underwent operative fixation were included in this trial to determine the safety and efficacy of a minimally invasive intervention through the percutaneous introduction of an aspirated bone marrow enriched Mesenchymal stem cell (MSC) graft in regards to union time, pain and quality of life. Included patients were randomized to the control group (no additional treatment) or the intervention, a prophylactic treatment consisting of a MSC composite graft 3 to 6 weeks after their initial operation. Results demonstrated a reduced time for union in the MSC composite graft group. No patients experienced nonunions in either group over the 12 month follow-up, but 3 patients in the control group experienced delayed unions. Pain and quality of life were equivalent between the two interventions. It should be noted that this pilot study was limited by the small sample size and the fact that it took place in a single-center.